Study of KTX-2001 for men with advanced prostate cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called KTX-2001, possibly combined with another drug (darolutamide), for men whose prostate cancer has spread and stopped responding to standard hormone treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of prostate cancer that has spread to other parts of the body and keeps growing even when testosterone is very low (called metastatic castration-resistant prostate cancer).
- Your cancer has gotten worse after treatment with an androgen receptor pathway inhibitor (such as abiraterone, enzalutamide, darolutamide, or apalutamide).
- You are willing to have a biopsy (tissue sample taken) of a tumor site before and during the study, unless a recent sample is available.
- Your liver, kidney, and blood cell counts are within adequate ranges as determined by blood tests.
- You do not have uncontrolled infections or serious heart conditions, and you have recovered from side effects of prior cancer treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
This trial tests whether adding the drug SX-682 to enzalutamide can help men whose prostate cancer has stopped responding to other hormone treatments. You may be eligible if your cancer is growing despite treatment with abiraterone, darolutamide, apalutamide, or enzalutamide.
This trial tests a new drug (TYK-00540) combined with enzalutamide for men whose prostate cancer has spread and is no longer responding to standard hormone therapy. It may be an option if you have tried only one other newer hormone treatment and it failed.
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
This early-phase trial tests a new oral drug, GT-220F, for men whose prostate cancer has spread and no longer responds to hormone therapy. It may be especially for patients whose cancer has specific genetic changes in the PTEN or PIK3CB genes.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.